SIGA Technologies, Inc. — FY2020 Form 10-K
Reporting period: Year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. SIGA is a commercial-stage pharmaceutical company whose lead product is oral TPOXX, an FDA-approved smallpox antiviral sold primarily through government stockpiling contracts.
Financial results and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $125.0 million | $26.7 million |
| Product sales and supportive services | $115.5 million | $11.2 million |
| Research and development revenue | $9.5 million | $15.6 million |
| Operating income (loss) | $84.5 million | $(2.3) million |
| Net income (loss) | $56.3 million | $(7.2) million |
| Diluted earnings (loss) per share | $0.71 | $(0.15) |
| Net cash provided by (used in) operations | $71.5 million | $(18.2) million |
- 2020 product revenue included $112.6 million from delivery of about 363,000 oral TPOXX courses to the U.S. Strategic National Stockpile and $2.3 million from Canadian military sales.
- Approximate product gross margin was 87% in 2020, calculated from product revenue less cost of sales; the filing attributes the change in gross margin to country pricing differences and updated production-agreement terms.
- Cash and cash equivalents were $117.9 million at year-end, versus $65.2 million in 2019. Inventory rose to $20.3 million from $9.7 million. Current assets were $143.6 million and current liabilities $10.5 million.
- The company repaid its term loan in March 2020 for approximately $87.2 million, including accrued interest and fees. Year-end debt and restricted cash were both zero. Repayment resulted in a $5.0 million extinguishment loss; interest expense fell to $3.0 million from $15.8 million.
- The company repurchased approximately 4.6 million shares for $28.5 million during 2020. A $50 million authorization runs through December 31, 2021; approximately $21.5 million remained available at year-end.
Material changes versus FY2019
- Revenue increased sharply, chiefly because SIGA delivered approximately 363,000 courses under exercised options in its 2018 BARDA contract; FY2019 product sales largely reflected an earlier, smaller delivery.
- The shift from a net loss to net income reflected higher product revenue and lower interest expense, partly offset by income tax expense of $17.2 million and a $3.5 million noncash loss from revaluing the warrant liability.
- Research and development revenue declined by $6.1 million. FY2019 included a $3.3 million cumulative catch-up adjustment for revised reimbursement rates; FY2020 R&D expense also declined, to $10.9 million from $13.3 million.
- Operating cash flow improved to $71.5 million, mainly with cash receipts tied to product deliveries, while financing cash use included the term-loan repayment and share repurchases.
Outlook, commentary and risks
- The 2018 BARDA contract contemplates up to approximately $602.5 million in total payments: $127.1 million related to exercised options and up to $423.7 million tied to unexercised options. BARDA alone decides whether and when to exercise those options; more than 90% of remaining contract value is option-dependent.
- SIGA estimates that about one million courses of smallpox antiviral treatment may need delivery to the U.S. government during 2021–2023 to maintain unexpired stockpile levels. This is an estimate, not a purchase commitment or company revenue guidance.
- SIGA expected to file an IV TPOXX new drug application as early as Q2 2021; approval, timing and any additional FDA requirements are uncertain. The company also filed an EU application in July 2020 and a Canadian application in December 2020 for oral tecovirimat.
- A January 2021 Canadian public-health contract provides for up to approximately $33 million in purchases over five years, including stated firm commitments; later quantities are subject to options. The company reported no finalized deliveries under that contract as of the filing. A separate Canadian military contract is for up to approximately $14 million, with $2.3 million purchased in Q2 2020 and remaining purchases subject to options and regulatory approval.
- Management reported no material COVID-19 disruption to the supply chain or current contract performance as of the filing, but noted slower government contracting activity and expected possible R&D delays. International contract timing and future pandemic effects remain uncertain.
- Key risks include dependence on government procurement and appropriations, discretionary BARDA options, fixed-price contract cost overruns, third-party manufacturing and supply-chain execution, regulatory approvals for IV and international markets, and reliance on Meridian for international promotion. The company had approximately $12.5 million in manufacturing purchase commitments at year-end.
- There is no specific revenue or earnings guidance in the filing. The auditor issued an unqualified opinion on the financial statements and identified estimation of costs to complete R&D performance obligations as a critical audit matter.
Important facts for investors to verify
- Whether and when BARDA exercises remaining procurement and IV-formulation options, and the resulting delivery schedule and contract economics.
- Progress, timing and outcome of the IV TPOXX FDA application and the EU and Canadian oral-product reviews.
- Actual deliveries, revenue recognition and cash collection under Canadian contracts, including option-dependent portions.
- Inventory readiness, manufacturing capacity, cost assumptions and the margin impact of contract pricing and production terms.
- Cash deployment after debt repayment, remaining share-repurchase activity, and the effect of outstanding warrant revaluation and potential dilution.